Boston, MA 02/24/2014 (wallstreetpr) – Sunedison Inc (NYSE:SUNE) was among the winners of clean energy permits in India. The company was alongside Azure Power India awarded 100 megawatts capacity each in the first national solar permits auction since 2012. The strategy that helped SUNE and other winners was that they placed the lowest bids. The government offered to offset about 30 percent in solar energy projects costs of which a total of $302 million was a located in grant. The Indian authorities ran a very competitive bidding process. The company that won the permits would sell their power at roughly 5.5 rupees per kilowatt-hour. The stock of Sunedison Inc (NYSE:SUNE) traded positively Friday, gaining 1.04 percent to touch a new 52-week high at $16.60 and later settling at $16.54.
Ocwen Financial Corp (NYSE:OCN) fared badly, or somewhat below expectations in its bond offering. The company garnered nearly $124 million in bond sales. However, underwriters had hoped that the same exercise could result approximately $136 million. The notes are secured by mortgage servicing rights. Experts say that the business of servicing is always expensive and thus may not be the best game for company struggling with costs. Recently OCN announced an “indefinite stop” to its efforts to acquire quite a significant mortgage servicing rights from Wells Fargo & Company (NYSE:WFC). The company is now working with the New York Department of Financial Services to iron out the emerging issues in the deal. As of the previous session, Ocwen Financial Corp (NYSE:OCN)’s stock gained 5.33 percent to push up the share price to $37.54.
Merck & Co., Inc. (NYSE:MRK) is not in its very best position at the moment. The company’s forecast implies possible revenue decline of about 3 percent this year. This is due to lack of significant product launches and competition from generic drug manufacturers. However, all is not lost for investors, and it even seem many investors understanding this already looking at the gains that the ticker has experienced on the browser since November. The company’s has opportunities of revenue growth in the near future due to its expanded focus on diabetes treatment and promising anti-infective treatments market. Merck & Co., Inc. (NYSE:MRK) recorded yet another gain in its stock price in the previous session to settle at $56.03.
